U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096063) titled 'Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk' on July 23.
Brief Summary: Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Study Start Date: Oct. 01, 2024
Study Type: OBSERVATIONAL
Condition:
Type 2 Diabetes
Overweight
Cardiovascular (CV) Risk
Intervention:
DRUG: Tirzepatide
New use of tirzepatide dispensing claim is used as...